Vireo Growth (VREOF) Cash & Equivalents (2020 - 2026)
Vireo Growth (VREOF) posted Cash & Equivalents of $137.8 million for Q1 2026, up 12.49% sequentially from $122.5 million in Q4 2025, and up 59.86% YoY from $86.2 million in Q1 2025.
Vireo Growth (VREOF) Cash & Equivalents (2020 - 2026) Analysis & Trends
Vireo Growth has reported Cash & Equivalents for 7 years, with the latest figure at $137.8 million in Q1 2026.
- Quarterly Cash & Equivalents rose 59.86% year-over-year to $137.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $137.8 million (up 59.86% YoY) and the FY2025 annual result came in at $122.5 million, up 33.73% from the prior year.
- Cash & Equivalents advanced to $137.8 million in Q1 2026 per VREOF's latest filing, from $122.5 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $137.8 million in Q1 2026 and troughed at $7.3 million in Q3 2024.
- A 5-year average of $47.0 million and a median of $16.0 million in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2025: Cash & Equivalents sank 78.79% in 2022, then jumped 1514.58% in 2025.
- Over 5 years, Cash & Equivalents stood at $15.1 million in 2022, then climbed by 5.38% to $16.0 million in 2023, then soared by 473.77% to $91.6 million in 2024, then soared by 33.73% to $122.5 million in 2025, then advanced by 12.49% to $137.8 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $137.8 million, $122.5 million, and $117.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 164.00 Mn |
| 10 | Vireo Growth | 492.80 Mn | 350.50 Mn | 95.30 Mn | 122.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 137.80 Mn |
| Dec 31, 2025 | 122.50 Mn |
| Sep 30, 2025 | 117.54 Mn |
| Jun 30, 2025 | 99.13 Mn |
| Mar 31, 2025 | 86.20 Mn |
| Dec 31, 2024 | 91.60 Mn |
| Sep 30, 2024 | 7.28 Mn |
| Jun 30, 2024 | 11.23 Mn |
| Mar 31, 2024 | 12.60 Mn |
| Dec 31, 2023 | 15.96 Mn |
| Sep 30, 2023 | 13.30 Mn |
| Jun 30, 2023 | 11.35 Mn |
| Mar 31, 2023 | 10.35 Mn |
| Dec 31, 2022 | 15.15 Mn |
| Sep 30, 2022 | 21.84 Mn |
| Jun 30, 2022 | 16.97 Mn |
| Mar 31, 2022 | 8.60 Mn |
| Dec 31, 2021 | 15.16 Mn |
| Sep 30, 2021 | 11.78 Mn |
| Jun 30, 2021 | 20.83 Mn |